Testing effectiveness (Phase 2)Ended earlyNCT01215578
What this trial is testing
Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
Who this might be right for
Neuroendocrine TumorsPancreatic NeoplasmsAdvanced Disease+1 more
Assistance Publique - Hôpitaux de Paris 33